Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

Fiona Blackhall, D. Ross Camidge, Alice T. Shaw, Jean Charles Soria, Benjamin J. Solomon, Tony Mok, Vera Hirsh, Pasi A. Jänne, Yuankai Shi, Pan Chyr Yang, Tommaso De Pas, Toyoaki Hida, Javier De Castro Carpeño, Silvana Lanzalone, Anna Polli, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Dong Wan Kim^*

^*Corresponding author for this work

Division of Cancer Sciences (L5)

University of Colorado Cancer Center
Massachusetts General Hospital
Institut de Cancerlogie Gustave Roussy
University of Melbourne
Chinese University of Hong Kong
McGill University Health Center
Harvard Medical School
Beijing Cancer Hospital
National Taiwan University Hospital
Istituto Europeo di Oncologia (IEO)
Aichi Cancer Center
Hospital Universitario La Paz
Inc.
Pfizer Oncology
Pfizer Global Innovative Pharma Business
Seoul National University Hospital

Research output: Contribution to journal › Article › peer-review

Sort by
Weight
Alphabetically

Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

Fingerprint

Pharmacology, Toxicology and Pharmaceutical Science